Side-by-side · Research reference
5-Amino-1MQvsPinealon
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft8/38 cited
BHuman-MechanisticDraft12/36 cited
5-Amino-1MQ
NNMT inhibitor · Methylation / SAM modulation
Oral · Once daily fasted
Pinealon
Pineal-derived · Neuroprotective
SQ or IM · Daily for 10 days · 1-2×/year
01Mechanism of Action
Parameter
5-Amino-1MQ
Pinealon
Primary target
Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018
Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014
Pathway
NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018
Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014
Downstream effect
Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018
Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014
Feedback intact?
—
—
Origin
Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018
Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014
Antibody development
—
—
02Dosage Protocols
Parameter
5-Amino-1MQ
Pinealon
Standard dose
100–200 mg / day oralNeelakantan 2018
Anecdotal community range; murine doses scaled.
5–10 mg / day for 10 daysKhavinson 2014
Frequency
Once daily, fasted
Once daily during cycle
Lower / starter dose
50 mg / day
2.5 mg / day
Evidence basis
Animal-strong; no human RCT dataNeelakantan 2018
Russian clinical trials + in vitroKhavinson 2014
Duration
8–12 weeks per cycle
10-day cycles, 1–2× per year
Form
Oral capsule
—
Timing
Morning fasted preferred
No specific time
Half-life
Hours (estimated; no human PK published)
Hours
Reconstitution
—
Bacteriostatic water
04Side Effects & Safety
Parameter
5-Amino-1MQ
Pinealon
GI symptoms
Mild nausea (anecdotal)
—
Methylation disruption
Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)
—
Long-term safety
Unknown — no human trials
Limited Western data
Cancer risk
Unclear — NNMT also studied in oncology contexts
—
Pregnancy / OB
Avoid
Avoid
Drug interactions
Theoretical with niacin / B-vitamin supplements
—
Injection site reaction
—
Mild irritation
Absolute Contraindications
5-Amino-1MQ
- ·Pregnancy / breastfeeding
- ·Active malignancy
Pinealon
- ·Pregnancy / breastfeeding
Relative Contraindications
5-Amino-1MQ
- ·Methylation-sensitive conditions (MTHFR mutation)
- ·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)
Pinealon
- ·Active malignancy (theoretical via gene expression modulation)
05Administration Protocol
Parameter
5-Amino-1MQ
Pinealon
1. Form
Oral capsule. No injection.
Add 1–2 mL bacteriostatic water to 10 mg vial.
2. Administration
Take with water, fasted preferred.
SQ — abdomen preferred.
3. Timing
Morning fasted.
Daily during cycle, any time.
4. Storage
Room temp ≤25 °C, dry place.
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
5. Caveat
Monitor B-vitamin status with chronic use.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
5-Amino-1MQ
— no documented stacks
Pinealon
+ Epitalon
ModeratePinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.
- Pinealon
- 5–10 mg SQ · daily × 10 days
- Epitalon
- 5–10 mg SQ · daily × 10 days (overlap or alternate)
- Primary benefit
- Neuroprotection + telomere preservation